Headquartered in Parsippany, NJ Fiscal year ends December NYSE: ZTS zoetis.com
Zoetis Inc. is an animal health company that discovers, develops, manufactures and sells medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals (dogs, cats and horses) and livestock (cattle, swine, poultry, fish and sheep). It serves veterinarians, livestock producers and pet owners in more than 100 countries.
The company manages its commercial operations through two segments: United States and International. It also has smaller contract manufacturing and human health activities.
Companion Animal is its largest business, anchored by:
- Parasiticides such as Simparica Trio.
- Osteoarthritis pain therapies such as Lenivia and Portela.
- Dermatology products, antibacterials such as Convenia, and vaccines such as Vanguard.
In livestock, it offers vaccines such as Fostera PRRS, parasiticides such as Dectomax, and aquaculture products.
In 2026 the company faces pressure in U.S. companion animal dermatology from competition and generics. It is pursuing a cost and productivity program, a multi-year ERP-based business transformation, and an accelerated slate of regulatory approvals. Updated
Management raised full-year adjusted EPS guidance to $6.25-$6.35 even with U.S. companion animal revenue down 8% on generic and dermatology competition, with livestock and fish sales filling the gap. The earnings report came in ahead of consensus.
Apple just got cut, BlackRock got a lift, and chipmakers are under pressure ahead of a week packed with big-tech earnings. Find out which stocks Wall Street is moving on Tuesday and…
Rescuing a dog or cat can easily turn into a 10- to 20-year financial commitment. Medium-sized dogs often live around 10 to 13 years, while many cats live into their mid-teens and…
Pre-Market Stock Futures: Futures are trading higher as we hit the mid-week point, as the technology-led rally continues to spiral higher. While the major indices finished the day mixed, the technology-heavy Nasdaq…
Morningstar’s Investing Insights podcast recently spotlighted four S&P 500 stocks that have already declared dividend increases of 10% or more, effectively locking in their place on next year’s Dividend Growers screen, which…
On a recent Morningstar Investing Insights segment unveiling the 2026 class of exceptional dividend growers, the host offered one caveat worth the entire show: “Valuation was not a component in this screen…
One of Wall Street’s top firms just gave a thumbs-up to Zoetis (NYSE:ZTS | ZTS Price Prediction) stock. Citi initiated coverage with a Buy rating and a $145 price target, naming it…
Pre-Market Stock Futures: Futures are trading lower as we prepare to finally end what has been one of the most volatile weeks in recent memory, with oil hitting its highest level since…
Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began…
The steep increase in pet healthcare costs have doubled over the past five years, according to NPR. There are a number of reasons for this trend, but the overall numbers are large,…
British billionaire investor Terry Smith is known as “the English Warren Buffett.” His London-based investment management firm, Fundsmith, was founded in 2010 and is known for Smith’s disciplined, long-term approach to investing.…
After years of a low-interest rate environment, which has reversed in a big way over the last 18 months, many investors continue to turn to equities not only for growth potential but…
Thursday's top analyst upgrades and downgrades included American Airlines, Amgen, Block, Chewy, First Solar, Nvidia, Southwest Airlines, Taiwan Semiconductor Manufacturing and Toast.
Friday's top analyst upgrades and downgrades included Arista Networks, DataDog, FedEx, Fiserv, Gilead Sciences, Global Payments, Nvidia, Oatly, Pfizer, Target, TJX Companies and Victoria’s Secret.
Monday's top analyst upgrades and downgrades included Accenture, Coca-Cola, Fastly, First Solar, Lemonade, Marvell Technology, Peloton Interactive and Target.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of…
Zoetis Inc. is an animal health company that discovers, develops, manufactures and sells medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals (dogs, cats and horses) and livestock (cattle, swine, poultry, fish and sheep).
24/7 Wall St.'s 12-month price target for ZTS is $96.58, rated Buy. The Wall Street consensus target is $89.69. ZTS price prediction →
